AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...

AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

We appreciate the opportunity to address the comments by Yangfan Cheng and colleagues, and Sebastian Walsh and colleagues regarding our Article on long-term gantenerumab treatment in dominantly ...

We read with great interest the Article by Randall J Bateman and colleagues investigating long-term gantenerumab treatment in dominantly inherited Alzheimer's disease.1 This important work provides ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

Anselamimab is an anti-fibril monoclonal antibody designed to reduce or eliminate amyloid deposits by binding with targets of amino acids on misfolded amyloid fibrils.

Later in the afternoon, Bloomberg reported that US President Donald Trump expects to fire the Federal Reserve chairman soon, ...

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

The CARES clinical programme is the largest prospective investigation in cardiac AL amyloidosis to date with a total of 406 patients enrolled from 19 countries globally, including 281 patients with ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival ...

AstraZeneca’s (NYSE:AZN) rare disease division, Alexion, announced that its experimental treatment anselamimab did not ...